Potential Immune Therapy Candidates

Immune Therapy for Dust Mite Allergy

Genetic Immunity is leveraging its nanomedicine immune amplification platform technology to develop the DermAll Patch, in which the NanoComp nanoparticle is formulated with a plasmid DNA encoding a special allergen. Similar to the DermaVir Patch treatment for HIV/AIDS, repeated administration of the DermAll Patch has the potential to control allergies.

The DermAll Patch development program is partnered with University Szeged, which is currently evaluating the product candidate in a mouse model. Beyond these studies, Genetic Immunity’s current infrastructure can easily support any near-term toxicity studies and cGMP manufacturing required to initiate clinical development.

Immune Therapies for Cancer

Genetic Immunity's immune therapy technology platform is potentially applicable for the development of new patch-based cancer nanomedicines with NanoComp nanparticles that contain plasmid DNA encoding tumor-specific antigens (e.g., proteins expressed only by tumor cells). The Company is currently considering several different research and development opportunities.

Immune Therapies for Emerging Infectious Diseases

Genetic Immunity may be able to leverage its immune amplification technology platform to develop nanomedicines for infectious diseases where T-cell responses can be directed against cells harboring intracellular pathogens. Potential indications include hepatitis C and B viruses, human papilloma virus (HPV), malaria, and Chlamydia. Despite significant competition crowding into these development areas, the Company is currently analyzing various opportunities. HPV, the infection that causes cervical cancer, is one application under consideration. Genetic Immunity can design plasmid DNA expressing the appropriate HPV sequences for evaluation in vitro or in vivo. The HPV nanomedicine candidate is expected to induce HPV-specific precursor T-cells that can proliferate and kill tumor cells harboring the virus. This is the same biological effect as the DermaVir Patch since the DNA sequence in the product composition is the only variable between the two.